Page last updated: 2024-09-05

lapatinib and bortezomib

lapatinib has been researched along with bortezomib in 13 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(bortezomib)
Trials
(bortezomib)
Recent Studies (post-2010) (bortezomib)
1,9193051,4426,8688604,753

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)bortezomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)0.5335
Proteasome subunit alpha type-7Homo sapiens (human)0.3213
Histone deacetylase 3Homo sapiens (human)1.18
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)0.5335
Cathepsin GHomo sapiens (human)1.81
Lysosomal protective proteinHomo sapiens (human)9.2
26S proteasome regulatory subunit 6AHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)0.085
Proteasome subunit beta type-1Homo sapiens (human)0.2149
ChymaseHomo sapiens (human)1.19
Proteasome subunit alpha type-1Homo sapiens (human)0.3213
Proteasome subunit alpha type-2Homo sapiens (human)0.3213
Proteasome subunit alpha type-3Homo sapiens (human)0.3213
Proteasome subunit alpha type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-8Homo sapiens (human)0.1681
Proteasome subunit beta type-8Mus musculus (house mouse)0.0168
Proteasome subunit beta type-9Homo sapiens (human)0.2059
Proteasome subunit alpha type-5Homo sapiens (human)0.3213
Proteasome subunit beta type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-6Homo sapiens (human)0.2842
Proteasome subunit beta type-5Homo sapiens (human)0.1407
26S proteasome regulatory subunit 7Homo sapiens (human)0.5335
Lon protease homolog, mitochondrialHomo sapiens (human)0.183
Proteasome subunit beta type-10Homo sapiens (human)0.5359
26S proteasome regulatory subunit 6BHomo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)0.5335
Proteasome subunit beta type-3Homo sapiens (human)0.3213
Proteasome subunit beta type-2Homo sapiens (human)0.9297
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome complex subunit SEM1Homo sapiens (human)0.5335
Proteasome subunit alpha type-6Homo sapiens (human)0.3213
26S proteasome regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome regulatory subunit 8Homo sapiens (human)0.5335
26S proteasome regulatory subunit 10BHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)0.085
Transcription factor p65Homo sapiens (human)0.085
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)0.5335
Histone deacetylase 1Homo sapiens (human)0.62
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)0.5335
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)0.5335
ATP-dependent Clp protease proteolytic subunitStaphylococcus aureus subsp. aureus NCTC 83255.3
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)0.0407
Proteasome subunit alpha-type 8Homo sapiens (human)0.3213
Histone deacetylase 2Homo sapiens (human)0.8
Proteasome subunit beta type-7Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)0.5335
Histone deacetylase 8Homo sapiens (human)0.072
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)0.5335

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (23.08)29.6817
2010's8 (61.54)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ajenjo, N; Albarrán, MI; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; Cuadrado-Urbano, M; García, AB; García-Serelde, B; Gómez de la Oliva, CA; Gómez-Casero, E; González Cantalapiedra, E; Hernández, AI; Klett, J; Martínez-González, S; Oyarzabal, J; Pastor, J; Rabal, O; Rodríguez-Arístegui, S; Varela, C1
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E1
Laurie, SA; Licitra, L1
Hatake, K1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E1
Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL1
Deeken, J; He, AR; Hwang, J; Lynce, F; Marshall, J; Petricoin, EF; Pishvaian, MJ; Pohlmann, PR; Smaglo, B; Subramaniam, DS; Wang, H1
Bazrgar, M; Hassani, SN; Masoudi, NS; Mirzaei-Seresht, B; Mollammohammadi, S; Sheidai, M1

Reviews

4 review(s) available for lapatinib and bortezomib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Systemic therapy in the palliative management of advanced salivary gland cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab

2006
[Breast cancer and Her-2].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2007
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab

2008

Trials

1 trial(s) available for lapatinib and bortezomib

ArticleYear
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptor, ErbB-2

2019

Other Studies

8 other study(ies) available for lapatinib and bortezomib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
    European journal of medicinal chemistry, 2019, Apr-15, Volume: 168

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinolines; Structure-Activity Relationship; Triazoles

2019
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
    European journal of medicinal chemistry, 2021, Jan-15, Volume: 210

    Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2

2021
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
    Cancer science, 2010, Volume: 101, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2

2010
[Renal tolerance of targeted therapies].
    Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3

    Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2012
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Breast cancer research : BCR, 2013, Nov-12, Volume: 15, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013
Chromosomal instability reducing effect of paclitaxel and lapatinib in mouse embryonic stem cells with chromosomal abnormality.
    Molecular biology reports, 2020, Volume: 47, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line; Chromosomal Instability; Lapatinib; Mice; Mouse Embryonic Stem Cells; Nanog Homeobox Protein; Octamer Transcription Factor-3; Paclitaxel; SOXB1 Transcription Factors

2020